Metabolic sequelae associated with androgen deprivation therapy for prostate cancer. - Wikidata - awgldk - TriplyDB

Metabolic sequelae associated with androgen deprivation therapy for prostate cancer.

Metabolic sequelae associated with androgen deprivation therapy for prostate cancer.

http://www.wikidata.org/entity/Q37431937

about

Physical functioning for prostate health Androgen receptor roles in insulin resistance and obesity in males: the linkage of androgen-deprivation therapy to metabolic syndrome Low testosterone associated with obesity and the metabolic syndrome contributes to sexual dysfunction and cardiovascular disease risk in men with type 2 diabetes Quantifying the evidence for the risk of metabolic syndrome and its components following androgen deprivation therapy for prostate cancer: a meta-analysis.Final Report of the Intergroup Randomized Study of Combined Androgen-Deprivation Therapy Plus Radiotherapy Versus Androgen-Deprivation Therapy Alone in Locally Advanced Prostate Cancer The Interactions between Insulin and Androgens in Progression to Castrate-Resistant Prostate Cancer Risk of diabetes among patients receiving primary androgen deprivation therapy for clinically localized prostate cancer Urological aspects of the metabolic syndrome.Testosterone and obesity.Role of free testosterone levels in patients with metastatic castration-resistant prostate cancer receiving second-line therapy.Metabolic syndrome in castration-resistant prostate cancer patients treated with abiraterone.ADT and the metabolic syndrome: no good deed goes unpunished.Effect of androgen deprivation therapy on cardiovascular risk factors in prostate cancer Klinefelter Syndrome and Metabolic Disorder.

P2860

Q26998875-6CE42B31-1105-4B2F-9A54-F862FA40CC96 Q34227893-EDD889AD-D7DF-455B-A86C-2CB0AA9D3467 Q35060256-6DA37A0B-11A3-4B26-B728-F1F17C7B7D74 Q35202889-7F3C5482-D6D5-4CFA-933B-4FE58C756E53 Q35771166-90E67C99-6649-4FF5-80B9-EE84842A5E1B Q35882782-05F60262-8502-4E6D-99B7-610DDF437F91 Q35977154-AA3BB0D1-1DFE-4453-806B-055C0D07DEC7 Q37910709-31E00605-E63B-4656-B439-9A6316B469DC Q38485746-6AD6E393-D36A-4A5F-9E0B-01EE29779135 Q38998655-B335C69F-C6B4-401D-A70C-757DFEF65D04 Q41732768-C721C260-3F7B-49FA-A54F-BCC381847CFD Q41809870-4BA71D70-BFAB-4F79-9781-20E354FD4D07 Q41881479-D9F282F8-897D-4F51-AF03-349BC7303A49 Q42338907-083FA52A-B444-4BE7-8E48-AD43151DA31F

P2860

Metabolic sequelae associated with androgen deprivation therapy for prostate cancer.

http://www.wikidata.org/entity/Q37431937

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on June 2010

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Metabolic sequelae associated with androgen deprivation therapy for prostate cancer.

@en

Metabolic sequelae associated with androgen deprivation therapy for prostate cancer.

@nl

type

label

Metabolic sequelae associated with androgen deprivation therapy for prostate cancer.

@en

Metabolic sequelae associated with androgen deprivation therapy for prostate cancer.

@nl

prefLabel

Metabolic sequelae associated with androgen deprivation therapy for prostate cancer.

@en

Metabolic sequelae associated with androgen deprivation therapy for prostate cancer.

@nl

P1433

Q37431937-C2046C13-A482-4821-ABF3-441C2DDE7584

P1476

Q37431937-31BC7164-5D37-4D1E-AA2E-C7861C8B8414

P2093

Q37431937-79F64C1A-E8E8-47CB-8088-189087AB04EF

Q37431937-D52B6B77-3B6E-4082-AA74-25B966BFEBF5

P2860

Q37431937-0053C6F6-37CB-49CB-818A-0F7460BEC211

Q37431937-007056E3-701D-4387-96C9-AFB0A593F22C

Q37431937-04A2D09F-9B50-462D-8C7A-AA10774BB3EB

Q37431937-04FDCE7B-0438-476F-A372-908EAC297B36

Q37431937-053A3EBD-EFE2-4712-B5F3-18805A467E45

Q37431937-080296C9-75E2-43FD-89F4-71EDCF3D1D81

Q37431937-0E961C2D-DE6F-4096-86BD-EAC912C4EB1F

Q37431937-0EEE8A69-8932-4569-B846-65465EE61E35

Q37431937-13D02AC2-CFCB-40CD-A3B9-3FCEBBC151AE

Q37431937-153E2A27-31E0-4155-AA71-128DA3265B25

P304

Q37431937-EEF33AC3-719B-4DBD-BC13-F4B0FD5114C2

P31

Q37431937-2AE3068C-2DC1-4F30-B23F-5C6F47AF7069

P356

Q37431937-758B17F0-4744-4136-B77F-AF098464E434

P433

Q37431937-189820FF-5036-4EE9-9DF9-1EC946BE720A

P478

Q37431937-06FB92C8-6D9B-4DC5-81F0-761D9C8BA23C

P577

Q37431937-F55BAD13-A1D2-4F4B-A3B4-45555AD12CB1

P698

Q37431937-91B65E50-8A43-437C-B1F4-570EBD11D3BC

P932

Q37431937-2E44AA9D-12B0-4E31-A090-0B508E0C64ED

P356

MED.0B013E3283391FD1

P1433

Current Opinion in Endocrinology, Diabetes and Obesity

P1476

Metabolic sequelae associated with androgen deprivation therapy for prostate cancer.

@en

P2093

Jason E Faris

http://www.w3.org/2001/XMLSchema#string

Matthew R Smith

http://www.w3.org/2001/XMLSchema#string

P2860

The Dark Side of Testosterone Deficiency: II. Type 2 Diabetes and Insulin Resistance

Metabolic complications of androgen deprivation therapy for prostate cancer

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy

Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths.

Testosterone, body composition and aging.

The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes.

Leuprolide versus diethylstilbestrol for metastatic prostate cancer.

6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.

The changing face of low-risk prostate cancer: trends in clinical presentation and primary management.

P304

240-246

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/MED.0B013E3283391FD1

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P577

2010-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20404727

http://www.w3.org/2001/XMLSchema#string

P932

5120548

http://www.w3.org/2001/XMLSchema#string